| INTELLIA THERAPEUTICS |
| USA |
| Gesundheit |
| US45826J1051 / A2AG6H |
| 38I (Frankfurt) / NTLA (NASDAQ) |
| FRA:38I, ETR:38I, 38I:GR, NASDAQ:NTLA |
| - |
| https://www.intelliatx.co.. |
|
Intellia Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genome-editing medicines built on CRISPR/Cas9 technology. Intellia Therapeutics develops both in vivo therapies, which edit genes inside the body, and ex vivo..
>Volltext.. |
| 1537.35 Mio. EUR |
| 1218.06 Mio. EUR |
| 51.24 Mio. EUR |
| -351.55 Mio. EUR |
| -344.44 Mio. EUR |
| -2.89 EUR |
| 63.22 Mio. EUR |
| 91.39 Mio. EUR |
| -298.51 Mio. EUR |
| 5.51 |
| 16.12% |
| 14.09% |
| - |
| - |
| - |
| INTELLIA |
| 08.09.26 |
|
||||
|